NATICK — Boston Scientific Corp. said European Union regulators have cleared marketing of its Promus Element stent for diabetes and heart attack patients.
Stents are mesh wire tubes that are used to hold arteries open after they have been surgically cleared of plaque. Some, like Promus Element, are coated with drugs to prevent scar tissue from blocking the artery again.
The company said it is aiming for approval of Promus Element in the United States and Japan in mid-2012.
Boston Scientific’s shares rose 5 cents, or 0.9 percent, to $5.59.